<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131219</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-aHUS-312</org_study_id>
    <secondary_id>2016‐002499‐29</secondary_id>
    <nct_id>NCT03131219</nct_id>
  </id_info>
  <brief_title>Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)</brief_title>
  <official_title>A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity in
      children and adolescents with aHUS who have not previously used a complement inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete TMA response</measure>
    <time_frame>26 weeks</time_frame>
    <description>The proportion of patients who achieved complete thrombotic microangiopathy (TMA) response as assessed by normalization of hematological parameters and ≥ 25% improvement in serum creatinine between Baseline and Day 183</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis requirement status</measure>
    <time_frame>26 weeks</time_frame>
    <description>The proportion of patients who do not require dialysis, among those who had received dialysis within 56 days prior to study drug treatment initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete TMA response</measure>
    <time_frame>26 weeks</time_frame>
    <description>Time from start of treatment to achievement of complete TMA response, defined as normalization of hematological parameters and ≥ 25% improvement in serum creatinine from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete TMA Response status over time</measure>
    <time_frame>26 weeks</time_frame>
    <description>Proportion of patients achieving complete TMA response at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed value and change from baseline in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Observed value and change from baseline in eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in chronic kidney disease (CKD) stage</measure>
    <time_frame>26 weeks</time_frame>
    <description>The number and proportion of patients with improvement, worsening, and no change in CKD stage compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hematologic parameters (platelets, lactate dehydrogenase (LDH), hemoglobin)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Observed value and change from baseline in platelets, LDH, and hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in hemoglobin of ≥ 20 g/L from baseline</measure>
    <time_frame>26 weeks</time_frame>
    <description>A proportion of patients with an increase in hemoglobin ≥ 20 g/L from baseline to Day 183</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life, as measured by Pediatric Functional Assessment of Chronic Therapy (FACIT) Fatigue questionnaire (patients ≥ 5 years of age)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in pediatric FACIT-Fatigue scores from baseline to Day 183</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome (aHUS)</condition>
  <arm_group>
    <arm_group_label>ALXN1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1210</intervention_name>
    <description>Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.</description>
    <arm_group_label>ALXN1210</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients from birth up to &lt; 18 years of age and weighing ≥ 5 kg at the time of
             consent.

          2. Evidence of thrombotic microangiopathy (TMA), including low platelet count, hemolysis
             (breaking of red blood cells inside of blood vessels), and decreased kidney function.

          3. Documented meningococcal vaccination not more than 3 years prior to dosing, and
             vaccination against Streptococcus pneumoniae and Haemophilus influenzae

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210

        Exclusion Criteria:

          1. ADAMTS13 deficiency (Activity &lt; 5%)

          2. Shiga toxin-related hemolytic uremic syndrome (STEC-HUS)

          3. Positive direct Coombs test

          4. Pregnancy or breastfeeding

          5. Identified drug exposure-related hemolytic uremic syndrome (HUS)

          6. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within last 6
             months prior to start of Screening

          7. HUS related to vitamin B12 deficiency

          8. Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or
             antiphospholipid antibody positivity or syndrome

          9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy
             for end-stage kidney disease (ESKD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals</last_name>
    <phone>475-230-ALXN (2596)</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fuchū</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Yangsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

